D.E. Shaw & Co
GRCL

D.E. Shaw & Co’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

D.E. Shaw & Co’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,356
Closed -$200K – 5333
2021
Q2 		$200K Buy
+15,356
New +$206K ﹤0.01% 4452

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co's GRCL Position: Q3 2021 in Review

D.E. Shaw & Co sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q3 2021, closing a stake of 15,356 shares — an estimated $200K sold.

D.E. Shaw & Co first reported a position in GRCL in Q2 2021 and held it in 1 quarter. The position peaked at $200K in Q2 2021. 34 funds tracked by Wall St. Rank hold GRCL as of Q3 2021.

  • D.E. Shaw & Co reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q3 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 15,356 Gracell Biotechnologies Inc. American Depositary Shares shares in Q3 2021, an estimated $200K.
  • D.E. Shaw & Co first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q2 2021 and held it in 1 quarter.
  • D.E. Shaw & Co's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $200K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.